{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"12.5","upperLimit":"NA","value":"44.1"},{"comment":"Not estimable due to the small number of events.","groupId":"OG001","lowerLimit":"26.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"DOR is defined for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \\[Cheson 2014\\]) to disease progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with an increased risk of tumor lysis syndrome (TLS) enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG000","title":"Safety Run-in: Increased TLS Risk at Baseline"},{"description":"Participants with an low risk of TLS enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG001","title":"Safety Run-in: Low TLS Risk at Baseline"}],"paramType":"MEDIAN","populationDescription":"All Enrolled Safety Run-in Subjects Achieving Response (Partial Response or Better)","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 74.78 months","title":"Duration of Response (DOR) (Safety Run-in)","type":"SECONDARY","unitOfMeasure":"months"}